Evaluation of efficacy, pharmacokinetics and tolerability of peptidomimetic aspartic proteinase inhibitors as cream formulation in experimental vaginal candidiasis

Journal of Pharmacy and Pharmacology

Volumn 66, Issue 8, 2014, Pages 1094-1101

  De Bernardis, Flavia ^a   Arancia, Silvia ^a   Tringali, Giuseppe ^b   Greco, Maria Cristina ^b   Ragazzoni, Enzo ^b   Calugi, Chiara ^b   Trabocchi, Andrea ^b   Sandini, Silvia ^a   Graziani, Sofia ^a   Cauda, Roberto ^c   Cassone, Antonio ^a   Guarna, Antonio ^b   Navarra, Pierluigi ^b  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

peptidomimetics; secreted aspartic proteinase inhibitors; vaginal experimental candidiasis

Indexed keywords

ANTIFUNGAL AGENT; APG 12; APG 19; CASPOFUNGIN; FLUCONAZOLE; UNCLASSIFIED DRUG; AGENTS USED INTRAVAGINALLY; ASPARTIC PROTEINASE; ECHINOCANDIN; PEPTIDOMIMETIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; CREAM; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; EXPERIMENTAL INFECTION; FEMALE; IN VIVO STUDY; NONHUMAN; PATHOGEN CLEARANCE; PATHOGEN LOAD; RABBIT; RAT; VAGINA CANDIDIASIS; VAGINITIS; ANIMAL; ANTAGONISTS AND INHIBITORS; CANDIDA ALBICANS; CANDIDIASIS; DRUG EFFECTS; MEDICINAL CHEMISTRY; PROCEDURES; WISTAR RAT;

ANIMALS; ANTIFUNGAL AGENTS; ASPARTIC ACID PROTEASES; CANDIDA ALBICANS; CANDIDIASIS; CHEMISTRY, PHARMACEUTICAL; ECHINOCANDINS; FEMALE; FLUCONAZOLE; PEPTIDOMIMETICS; RATS; RATS, WISTAR; VAGINAL CREAMS, FOAMS, AND JELLIES; VAGINITIS;

EID: 84904254824     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12240     Document Type: Article

References (26)

1. Sobel JD,. Vulvovaginal candidiasis. Lancet 2007; 369: 1961-1971.
2. Fidel PL Jr,. History and update on host defense against vaginal candidiasis. Am J Reprod Immunol 2007; 57: 2-12.
3. Sanglard D, Odds FC,. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis 2002; 2: 73-78.
4. Shao PL, etal. Recent advances and challenges in the treatment of invasive fungal infections. Int J Antimicrob Agents 2007; 30: 487-495.
5. Naglik JR, etal. Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol Mol Biol Rev 2003; 67: 400-428.
6. Naglik JR, etal. Quantitative expression of the Candida albicans secreted aspartyl proteinase gene family in human oral and vaginal candidiasis. Microbiology 2008; 154: 3266-3280.
7. Gauwerky K, etal. Targeting virulence: a new paradigm for antifungals. Drug Discov Today 2009; 14: 214-222.
8. Braga-Silva LA, Santos AL,. Aspartic proteinase inhibitors as potential anti-Candida albicans drugs: impacts on fungal biology, virulence and pathogenesis. Curr Med Chem 2011; 18: 2401-2419.
9. Schaller M, etal. Invasion of Candida albicans correlates with expression of secreted aspartic proteinases during experimental infection of human epidermis. J Invest Dermatol 2000; 114: 712-717.
10. De Bernardis F, etal. Aspartyl proteinases of Candida albicans and their role in pathogenicity. Med Mycol 2001; 39: 303-313.
11. De Bernardis F, etal. Human domain antibodies against virulence traits of Candida albicans inhibit fungus adherence to vaginal epithelium and protect against experimental vaginal candidiasis. J Infect Dis 2007; 195: 149-157.
12. Sandini S, etal. A highly immunogenic recombinant and truncated protein of the secreted aspartic proteases family (rSap2t) of Candida albicans as a mucosal anticandidal vaccine. FEMS Immunol Med Microbiol 2011; 62: 215-224.
13. Naglik J, etal. Candida albicans proteinases and host/pathogen interactions. Cell Microbiol 2004; 6: 915-926.
14. Schaller M, etal. Hydrolytic enzymes as virulence factors of Candida albicans. Mycoses 2005; 48: 365-377.
15. Trabocchi A, etal. Design, synthesis, and applications of 3-aza-6,8-dioxa-bicyclo[3.2.1]octane-based scaffolds for peptidomimetic chemistry. Synlett 2006; 3: 331-353.
16. Trabocchi A, etal. Identification of inhibitors of drug-resistant Candida albicans strains from a library of bicyclic peptidomimetic compounds. J Med Chem 2010; 53: 2502-2509.
17. Calugi C, etal. Byciclic peptidomimetics targeting secreted aspartyl protease 2 (SAP2) from Candida albicans reveal a constrained inhibitory chemotype. Bioorg Med Chem 2012; 20: 7206-7213.
18. De Bernardis F, etal. Expression of Candida albicans SAP-1 and SAP-2 in experimental vaginitis. Infect Immun 1995; 63: 1887-1892.
19. De Bernardis F, etal. Evidence that members of the secretory aspartyl proteinases gene family (SAP), in particular SAP2, are virulence factors for Candida vaginitis. J Infect Dis 1999; 179: 201-208.
20. Machetti F, etal. Neat reaction of carboxylic acid methyl esters and amines for efficient parallel synthesis of scaffold amide libraries. C R Chimie 2003; 6: 630-631.
21. Machetti F, etal. Parallel synthesis of an amide library based on the 6,8-dioxa-3-azabicyclo[3.2.1] octane scaffold by direct aminolysis of methyl esters. J Comb Chem 2007; 9: 454-461.
22. Powderly WG, etal. Diagnosis and treatment of oropharyngeal candidiasis in patients infected with HIV: a critical reassessment. AIDS Res Hum Retroviruses 1999; 15: 1405-1412.
23. McNeil MM, etal. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 2001; 33: 641-647.
24. Foxman B, etal. Prevalence of recurrent vulvovaginal candidiasis in 5 European countries and the United States: results from an Internet panel survey. J Low Genit Tract Dis 2013; 17: 340-345.
25. De Bernardis F, etal. High aspartyl proteinase production and vaginitis in human immunodeficiency virus infected women. J Clin Microbiol 1999; 37: 1376-1380.
26. Martins MD, etal. Declining rates of oropharyngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fluconazole-resistant C. albicans in human immunodeficiency virus-infected patients. Clin Infect Dis 1998; 7: 1291-1294.